top of page
mdi arrows.png

MDI's Unique Platform

MDI focuses on proteins not only because they are the primary functional molecules within the cell, and are much more chemically diverse than nucleic acids, but also because proteomic analysis condenses regulatory effects occurring at all levels of gene expression. DNA and RNA sequence information are not sufficient to predict the biological function of a protein, and gene expression does not always correlate with pathway activation level and/or does not fully predict a disease state.

Understanding what is happening at the protein level, including its activation status and post-translational modifications such as phosphorylation, acetylation, and glycosylation, is critical for diagnosing and monitoring disease progression, establishing individual prognosis, confirming genomic predictions, and tracking treatment responses.


MDI’s tests have been performed on several types of samples (i.e. tumors, tissues, and blood) and only require nanoscale amounts of material, easily collected via fine-needle aspirates or minimal blood draws. The tests can be performed at multiple time-points and give results in less than 24 hours. The high-throughput capability of the platform also makes it ideally suited for accumulating large data sets for novel biomarker identification, which can help with patient stratification in future clinical trials. 

  • Quantitative proteomics analysis in limited patient samples

  • Biomarker assessment and molecular diagnostics

  • Serial sampling analysis for target assessment and treatment/therapy response

  • Development of pharmacodynamic and predictive biomarkers

  • Disease detection and diagnosis

  • Detection and identification of post-translational modifications

  • Signaling pathways analysis

  • Quality assessment in development and manufacture of biological drugs


  • Automation and robust performance

  • Good intra- and inter-assay reproducibility with %CV of less than 5%

  • Detection sensitivity is much greater than that of other techniques and expressed proteins can be quantitatively assessed in less than 25 cells, making it ideal for FNA and small clinical samples

  • High dynamic range: linearity analysis over several orders of magnitude can be achieved 

  • Fast assay turnaround time: in a high-throughput mode, 96 samples can be analyzed within a 12-hour total turnaround time

  • Accurate data quantitation

Technology Advantages:


MDI's unique proteomic-based NIA tests are performed using Protein Simples' Peggy Sue platform which allows for resolving specific protein targets by molecular weight or charge. 


1.Hoerner, C., et al., Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma European Urology Oncology, 2018

2.Gouw, A., et al, Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma PNAS, 2017

3.Swords, R.T., et al, Lancet, KB004, a first in class monoclonal antibody targeting the receptortyrosine kinase EphA3, in patients with advanced hematologicmalignancies: Results from a phase 1 study Leukemia Research, 2016

4.Fan, A., et al, Real-Time Nanoscale Proteomic Analysis of the Novel Multi-Kinase Pathway Inhibitor Rigosertib to Measure the Response to Treatment of Cancer Expert Opin Investig Drugs, 2013

5.Seetharam, M, et al., Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na Leukemia Research, 2012

6.DeChristopher, B.A., et al.,  “Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYCInduced Lymphoma In Vivo Oncotarget, 2012

7.Fan, A., et al, Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens Nature Medicine, 2009

bottom of page